Treatment of Neurosarcoidosis in the Acutely and Severely Ill with Severe Disabling Neurologic Disease

Clinical Scenario

This protocol covers patients who are acutely and severely ill, presenting with severe, disabling neurologic disease attributable to neurosarcoidosis — a high-acuity presentation requiring prompt, structured management.

Presentation Context

Patients in this setting carry significant neurologic compromise. For those who are acutely and severely ill, intravenous corticosteroid therapy or anti-TNF therapy represents an established initial approach.

Treatment Approach

The protocol for this presentation involves combination immunosuppressive therapy — pairing a corticosteroid with an additional immunosuppressive agent — with the specific choice guided by clinical factors. Procedural interventions may also be appropriate for selected patients.

The complete structured regimen — including all treatment options, sequencing, clinical decision points, and procedural considerations — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

For patients who are acutely and severely ill, intravenous methylprednisolone for three days or anti-TNF therapy is recommended.
Mycophenolate and cyclophosphamide have been reported as useful for refractory neurosarcoidosis in selected cases.
Case studies suggest that cyclophosphamide is effective for some people and is perhaps particularly useful in severe disabling neurosarcoidosis that has not responded to other therapies, including intravenous corticosteroids and anti-TNF therapy.

View source ↗